{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:14:47Z","timestamp":1791530087353,"version":"4.3.4"},"reference-count":82,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.jfo.2019.02.002","type":"journal-article","created":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T08:52:17Z","timestamp":1551775937000},"page":"e133-e146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Eye and Beh\u00e7et's disease"],"prefix":"10.1016","volume":"42","author":[{"given":"I.","family":"Ksiaa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Abroug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kechida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Zina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Jelliti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Khochtali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Attia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Khairallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2019.02.002_bib0415","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0190-9622(97)80318-0","article-title":"Cutaneous vasculitis in Beh\u00e7et's disease: a clinical and histopathologic study of 20 patients","volume":"36","author":"Chen","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jfo.2019.02.002_bib0420","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.berh.2004.02.008","article-title":"Beh\u00e7et's disease","volume":"18","author":"Marshall","year":"2004","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.jfo.2019.02.002_bib0425","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","article-title":"Beh\u00e7et's disease","volume":"341","author":"Sakane","year":"1999","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jfo.2019.02.002_bib0430","series-title":"Uveitis. Fundamentals and clinical practice","first-page":"350","author":"Nussenblatt","year":"2004"},{"key":"10.1016\/j.jfo.2019.02.002_bib0435","first-page":"S58","article-title":"Adalimumab for treatment of severe Beh\u00e7et's uveitis: a retrospective long-term follow-up study","volume":"32","author":"Interlandi","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jfo.2019.02.002_bib0440","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00296-009-1213-z","article-title":"One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Beh\u00e7et's disease refractory to standard immunosuppressive drugs","volume":"31","author":"Giardina","year":"2011","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jfo.2019.02.002_bib0445","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3109\/09273948.2012.723112","article-title":"Epidemiology of Beh\u00e7et disease","volume":"20","author":"Khairallah","year":"2012","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jfo.2019.02.002_bib0450","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/archopht.1970.00990040453009","article-title":"The rate of visual loss in Beh\u00e7et's disease","volume":"84","author":"Mamo","year":"1970","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jfo.2019.02.002_bib0455","series-title":"Ocular infection and immunity","first-page":"663","article-title":"Beh\u00e7et's disease","author":"Mochizuki","year":"1996"},{"key":"10.1016\/j.jfo.2019.02.002_bib0460","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3109\/08830189709116845","article-title":"Uveitis in Beh\u00e7et's disease","volume":"14","author":"Nussenblatt","year":"1997","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.jfo.2019.02.002_bib0465","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/01.icu.0000247411.59213.bb","article-title":"Beh\u00e7et's disease: general concepts and recent advances","volume":"17","author":"Okada","year":"2006","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.jfo.2019.02.002_bib0470","series-title":"Uveitis. Text and imaging. 1st Ed.","first-page":"397","article-title":"Beh\u00e7et's disease","author":"Tugal-Tutkun","year":"2009"},{"key":"10.1016\/j.jfo.2019.02.002_bib0475","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/sj.eye.6702111","article-title":"Pattern of uveitis in a referral centre in Tunisia, North Africa","volume":"21","author":"Khairallah","year":"2007","journal-title":"Eye"},{"key":"10.1016\/j.jfo.2019.02.002_bib0480","doi-asserted-by":"crossref","first-page":"653539","DOI":"10.1155\/2014\/653539","article-title":"Immunopathogenesis of ocular Beh\u00e7et's disease","volume":"2014","author":"Park","year":"2014","journal-title":"J Immunol Res"},{"key":"10.1016\/j.jfo.2019.02.002_bib0485","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/BOR.0000000000000234","article-title":"Genetics of Beh\u00e7et's disease","volume":"28","author":"Morton","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jfo.2019.02.002_bib0490","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1076\/ocii.7.2.69.4018","article-title":"Beh\u00e7et's disease and antibody titers to various heat shock protein 60s","volume":"7","author":"Tanaka","year":"1999","journal-title":"Ocul Immunol Inflam"},{"key":"10.1016\/j.jfo.2019.02.002_bib0495","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.imlet.2018.07.001","article-title":"Evaluation of SOCS1 Methylation in patients with Behcet's disease","volume":"203","author":"Abdi","year":"2018","journal-title":"Immunol Lett"},{"key":"10.1016\/j.jfo.2019.02.002_bib0500","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.autrev.2017.12.006","article-title":"Beh\u00e7et's disease: new insights into pathophysiology, clinical features and treatment options","volume":"17","author":"Greco","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jfo.2019.02.002_bib0505","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12016-007-8064-8","article-title":"The unique features of vasculitis in Beh\u00e7et's syndrome","volume":"35","author":"Melikoglu","year":"2008","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jfo.2019.02.002_bib0510","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1016\/j.jfo.2017.07.008","article-title":"Retinal arterial occlusion associated with meningoencephalitis in the Behcet disease: case report","volume":"41","author":"Omari","year":"2018","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jfo.2019.02.002_bib0515","series-title":"Diagnosis and treatment of uveitis","first-page":"632","article-title":"Adamantiades-Beh\u00e7et disease","author":"Zafirakis","year":"2002"},{"key":"10.1016\/j.jfo.2019.02.002_bib0520","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.preteyeres.2007.09.002","article-title":"Beh\u00e7et's disease: ocular effects and treatment","volume":"27","author":"Deuter","year":"2008","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.jfo.2019.02.002_bib0525","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0161-6420(03)00265-3","article-title":"Conjunctival ulcers in Beh\u00e7et's disease","volume":"110","author":"Zamir","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2019.02.002_bib0530","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1442-9071.2006.01181.x","article-title":"Orbital inflammation associated with Beh\u00e7et's disease","volume":"34","author":"Hammami","year":"2006","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2019.02.002_bib0535","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3109\/09273948.2015.1108444","article-title":"Evaluation of intraocular inflammation with laser flare photometry in Beh\u00e7et uveitis","volume":"25","author":"Yalcindag","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jfo.2019.02.002_bib0540","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00417-008-0823-6","article-title":"Use of laser flare-cell photometry to quantify intraocular inflammation in patients with Beh\u00e7et uveitis","volume":"246","author":"Tugal-Tutkun","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2019.02.002_bib0545","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/bjo.70.8.589","article-title":"Treatment and visual prognosis in Beh\u00e7et's disease","volume":"70","author":"Ben Ezra","year":"1986","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2019.02.002_bib0550","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","article-title":"Uveitis in Beh\u00e7et's disease: an analysis of 880 patients","volume":"138","author":"Tugal-Tutkun","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2019.02.002_bib0555","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10792-008-9203-9","article-title":"Pattern of uveitis in Beh\u00e7et's disease in a referral center in Tunisia, North Africa","volume":"29","author":"Khairallah","year":"2009","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.jfo.2019.02.002_bib0560","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1097\/IAE.0000000000000197","article-title":"Use of ultra-wide-field retinal imaging in the management of active Beh\u00e7et retinal vasculitis","volume":"34","author":"Mesquida","year":"2014","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2019.02.002_bib0565","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/09273948.2016.1175640","article-title":"Inter-observer variability in scoring ultra-wide-field fluorescein angiography in patients with Beh\u00e7et retinal vasculitis","volume":"25","author":"Moon","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jfo.2019.02.002_bib0570","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/09273948.2016.1205100","article-title":"Review for diagnostics of the year: multimodal imaging in Beh\u00e7et uveitis","volume":"25","author":"Tugal-Tutkun","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jfo.2019.02.002_bib0575","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1097\/IAE.0000000000001418","article-title":"Optical coherence tomography angiography in patients with Beh\u00e7et uveitis","volume":"37","author":"Khairallah","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2019.02.002_bib0580","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12348-012-0075-9","article-title":"Macular involvement in patients with Beh\u00e7et uveitis","volume":"2","author":"Kahloun","year":"2012","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"10.1016\/j.jfo.2019.02.002_bib0585","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/eye.2009.231","article-title":"Structural changes of fovea during remission of Beh\u00e7et's disease as imaged by spectral domain optical coherence tomography","volume":"24","author":"Unoki","year":"2010","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jfo.2019.02.002_bib0590","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/00061198-200412000-00002","article-title":"Incidence of secondary glaucoma in Beh\u00e7et disease","volume":"13","author":"Elgin","year":"2004","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jfo.2019.02.002_bib0595","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3109\/09273948.2011.582219","article-title":"Branch retinal artery occlusion associated with Beh\u00e7et disease","volume":"19","author":"Ben Yahia","year":"2011","journal-title":"Ocul Imm Inflam"},{"key":"10.1016\/j.jfo.2019.02.002_bib0600","series-title":"Uveitis and immunological disorders","first-page":"173","article-title":"Beh\u00e7et's disease","author":"Zierhut","year":"2005"},{"key":"10.1016\/j.jfo.2019.02.002_bib0605","first-page":"565","article-title":"Criteria for diagnosis of Beh\u00e7et's syndrome","volume":"76","author":"Hewitt","year":"1969","journal-title":"Bull Soc Fr Dermatol Syphiligr"},{"key":"10.1016\/j.jfo.2019.02.002_bib0610","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/ard.28.2.95","article-title":"Beh\u00e7et's syndrome with arthritis","volume":"28","author":"Mason","year":"1969","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jfo.2019.02.002_bib0615","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/0002-9343(76)90166-2","article-title":"Neurologic involvement in seven patients with Beh\u00e7et's disease","volume":"61","author":"O\u2019Duffy","year":"1976","journal-title":"Am J Med"},{"key":"10.1016\/j.jfo.2019.02.002_bib0620","first-page":"59","article-title":"Recent research into Behcet's disease in Japan","volume":"10","author":"Mizushima","year":"1988","journal-title":"Int J Tissue React"},{"key":"10.1016\/j.jfo.2019.02.002_bib0625","first-page":"1078","article-title":"Criteria for diagnosis of Beh\u00e7et's disease","volume":"335","author":"International Study Group for Beh\u00e7et's disease","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.jfo.2019.02.002_bib0630","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/jdv.12107","article-title":"The International Criteria for Beh\u00e7et's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria","volume":"28","author":"International Team for the Revision of the International Criteria for Beh\u00e7et's Disease (ITR-ICBD)","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jfo.2019.02.002_bib0635","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.revmed.2009.04.014","article-title":"Ocular manifestations of Beh\u00e7et's disease","volume":"31","author":"Saadoun","year":"2010","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.jfo.2019.02.002_bib0640","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s13317-016-0074-1","article-title":"Beh\u00e7et disease physiopathology: a cotemporary review","volume":"7","author":"Zeidan","year":"2016","journal-title":"Auto Immun Highlights"},{"key":"10.1016\/j.jfo.2019.02.002_bib0645","first-page":"7","article-title":"Beh\u00e7et oculaire\u00a0: aspects pratiques","volume":"280","author":"Postelmans","year":"2001","journal-title":"Bull Soc Belge Ophtalmol"},{"key":"10.1016\/j.jfo.2019.02.002_bib0650","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1749-6632.2009.04756.x","article-title":"HLA-B27 and HLA-B51 determination in Tunisian healthy subjects and patients with suspected ankylosing spondylitis and Beh\u00e7et's disease","volume":"1173","author":"Sakly","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jfo.2019.02.002_bib0655","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/ard.2007.080432","article-title":"EULAR recommendations for the management of Beh\u00e7et's disease","volume":"67","author":"Hatemi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jfo.2019.02.002_bib0660","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/ICU.0b013e32834bbe91","article-title":"Ocular Beh\u00e7et disease: current therapeutic approaches","volume":"22","author":"Evereklioglu","year":"2011","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.jfo.2019.02.002_bib0665","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3109\/08820538.2011.588665","article-title":"The use of biologic agents in the treatment of ocular manifestations of Behcet's disease","volume":"26","author":"Benitah","year":"2011","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.jfo.2019.02.002_bib0670","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00296-008-0606-8","article-title":"Safety and efficacy of infliximab therapy in active Behcet's uveitis: an open-label trial","volume":"29","author":"Al-Rayes","year":"2008","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jfo.2019.02.002_bib0675","doi-asserted-by":"crossref","first-page":"451675","DOI":"10.1155\/2015\/451675","article-title":"Mucocutaneous involvement in Beh\u00e7et's disease: how systemic treatment has changed in the last decades and future perspectives","volume":"2015","author":"Rotondo","year":"2015","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jfo.2019.02.002_bib0680","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/acr.20308","article-title":"Azathioprine in severe uveitis of Beh\u00e7et's disease","volume":"62","author":"Saadoun","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jfo.2019.02.002_bib0685","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Beh\u00e7et's syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jfo.2019.02.002_bib0690","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3129\/i08-080","article-title":"Beh\u00e7et's disease comparing three decades of treatment response at the National Eye Institute","volume":"43","author":"Kump","year":"2008","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.jfo.2019.02.002_bib0695","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/bjo.76.4.241","article-title":"Low-dose cyclosporine A versus pulsed cyclophosphamide in Beh\u00e7et's syndrome: a single masked trial","volume":"76","author":"Ozzyazgan","year":"1992","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2019.02.002_bib0700","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1046\/j.1442-9071.2001.00445.x","article-title":"Central nervous system symptoms in a population of Beh\u00e7et's disease patients with refractory uveitis treated with cyclosporine A","volume":"29","author":"Kato","year":"2001","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2019.02.002_bib0705","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1076\/ocii.6.2.101.4051","article-title":"Tacrolimus (FK506) in failed cyclosporine A therapy in endogenous posterior uveitis","volume":"6","author":"Kilmartin","year":"1998","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jfo.2019.02.002_bib0710","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H","article-title":"A double-blind trial of colchicine in Behcet's syndrome","volume":"44","author":"Yurdakul","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jfo.2019.02.002_bib0715","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/archophthalmol.2011.3","article-title":"Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Beh\u00e7et uveitis","volume":"129","author":"Onal","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jfo.2019.02.002_bib0720","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/09273948.2015.1133835","article-title":"Interferon Alpha-2a therapy in patients with refractory Beh\u00e7et uveitis","volume":"25","author":"Hasanreisoglu","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jfo.2019.02.002_bib0725","first-page":"1","article-title":"Long-term efficacy of interferon in severe uveitis associated with Beh\u00e7et disease","volume":"19","author":"Diwo","year":"2016","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jfo.2019.02.002_bib0730","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1755-3768.2011.02348.x","article-title":"Light on the horizon: biologicals in Beh\u00e7et uveitis","volume":"91","author":"Hazirolan","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jfo.2019.02.002_bib0735","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2013.09.048","article-title":"Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders","volume":"121","author":"Levy-Clarke","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2019.02.002_bib0740","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.survophthal.2015.06.004","article-title":"Anti-tumor necrosis factor-\u03b1 therapy in uveitis","volume":"60","author":"Cordero-Coma","year":"2015","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jfo.2019.02.002_bib0745","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/bjo.2009.158840","article-title":"Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Beh\u00e7et disease","volume":"94","author":"Yamada","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2019.02.002_bib0750","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/eye.2014.138","article-title":"Long-term efficacy of infliximab on background vascular leakage in patients with Beh\u00e7et's disease","volume":"28","author":"Keino","year":"2014","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jfo.2019.02.002_bib0755","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.ophtha.2014.04.042","article-title":"Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Beh\u00e7et's disease: a multicenter study","volume":"121","author":"Takeuchi","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2019.02.002_bib0760","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/rheumatology\/keq366","article-title":"A single infliximab infusion vs. corticosteroids for acute panuveitis attacks in Beh\u00e7et's disease: a comparative 4-week study","volume":"50","author":"Markomichelakis","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jfo.2019.02.002_bib0765","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/art.39667","article-title":"Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French Uveitis Network","volume":"68","author":"Vallet","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jfo.2019.02.002_bib0770","first-page":"S93","article-title":"Efficacy of switching to adalimumab in a patient with refractory uveitis of Beh\u00e7et's disease to infliximab","volume":"29","author":"Leccese","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jfo.2019.02.002_bib0775","first-page":"98","article-title":"Short-term trial of etanercept in Behcet's disease: a double-blind, placebo-controlled study","volume":"32","author":"Melikoglu","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jfo.2019.02.002_bib0780","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/09273948.2012.741744","article-title":"Beh\u00e7et disease-associated uveitis successfully treated with golimumab","volume":"21","author":"Mesquida","year":"2013","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jfo.2019.02.002_bib0785","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1136\/bjo.85.11.1287","article-title":"Intravenous immunoglobulin therapy for resistant ocular Beh\u00e7et's disease","volume":"85","author":"Seider","year":"2001","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2019.02.002_bib0790","doi-asserted-by":"crossref","first-page":"107421","DOI":"10.1155\/2014\/107421","article-title":"Biological treatments in Beh\u00e7et's disease: beyond anti-TNF therapy","volume":"2014","author":"Caso","year":"2014","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jfo.2019.02.002_bib0795","first-page":"152","article-title":"Anakinra for resistant Beh\u00e7et uveitis: why not?","volume":"31","author":"Emmi","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jfo.2019.02.002_bib0800","first-page":"1","article-title":"Use of gevokizumab in patients with Beh\u00e7et's disease uveitis: an international, randomized, double-masked, placebo-controlled study and open-label extension study","volume":"25","author":"Tugal-Tutkun","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jfo.2019.02.002_bib0805","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/rheumatology\/kex480","article-title":"Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Beh\u00e7et's disease: multicentre retrospective study","volume":"57","author":"Atienza-Mateo","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jfo.2019.02.002_bib0810","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/BF00695247","article-title":"Retinal and disc neovascularization in Beh\u00e7et's disease and efficacy of laser photocoagulation","volume":"234","author":"Atmaca","year":"1996","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2019.02.002_bib0815","first-page":"1437","article-title":"Complete regression of retinal neovascularisation after therapy with interferon alfa in Beh\u00e7et's disease","volume":"84","author":"St\u00fcbiger","year":"2000","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2019.02.002_bib0820","first-page":"1","article-title":"\u0152il et maladie de Beh\u00e7et","volume":"15","author":"Khairallah","year":"2017","journal-title":"EMC\u00a0\u2013\u00a0Ophtalmol"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551219300683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551219300683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:09:39Z","timestamp":1759259379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0181551219300683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":82,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0181551219300683"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2019.02.002","relation":{},"ISSN":["0181-5512"],"issn-type":[{"value":"0181-5512","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eye and Beh\u00e7et's disease","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2019.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}